JCCVS
Journal of Cardiology & Cardiovascular Surgery

Journal of Cardiology & Cardiovascular Surgery scientific, open-access, double-blind peer-reviewed journal covering a wide spectrum of topics in cardiology and cardiovascular surgery.

eISSN: 2980-1397
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Beyond glucose: SGLT2 inhibitors as foundational therapy in heart failure
Abstract
Heart failure affects over 64 million people worldwide and remains a leading cause of hospitalization, death, and health care costs. Despite advances with renin angiotensin aldosterone system inhibitors, beta blockers, and mineralocorticoid receptor antagonists, survival gains remain modest, and outcomes in preserved ejection fraction disease have historically been poor. This review examines how sodium glucose cotransporter 2 inhibitors, initially developed as glucose lowering agents, have redefined heart failure therapy. We synthesize mechanistic insights, pivotal trial data, and evolving guidelines to clarify their role as foundational treatment across the ejection fraction spectrum. Evidence was drawn from cardiovascular outcome studies, dedicated heart failure trials, mechanistic investigations, and international guidelines, with focus on physiologic mechanisms, efficacy, and safety. Sodium glucose cotransporter 2 inhibitors provide benefits that extend beyond glucose control. They promote sustained diuresis, improve myocardial energetics, reduce inflammation and fibrosis, and protect renal function. Landmark trials including DAPA HF, EMPEROR Reduced, EMPEROR Preserved, and DELIVER consistently reduced hospitalizations and cardiovascular death across reduced, mildly reduced, and preserved ejection fraction populations, regardless of diabetes status. Benefits emerge early, improve quality of life, and are supported by a favorable safety profile. These findings have rapidly reshaped international guidelines, positioning these drugs alongside renin angiotensin system inhibitors, beta blockers, and mineralocorticoid receptor antagonists as pillars of therapy. Sodium glucose cotransporter 2 inhibitors represent one of the most important therapeutic breakthroughs in cardiovascular medicine, transforming heart failure care from discovery to global standard. The challenge ahead is ensuring equitable access, early adoption, and expanded exploration across cardiometabolic disease.

Keywords : SGLT2 inhibitor, heart failure, mortality

Download Article


1. Lam CSP, Harding E, Bains M, et al. Identification of urgent gaps in public and policymaker knowledge of heart failure: results of a global survey. BMC Public Health. 2023;23(1):1023. doi:10.1186/s12889-023-15405-4
2. Bozkurt B, Ahmad T, Alexander KM, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure Society of America. J Card Fail. 2023;29(10):1412-1451. doi:10.1016/j.cardfail.2023.07.006
3. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2
4. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720
5. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi:10.1056/NEJMoa1611925
6. Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14. doi:10.3390/diseases8020014
7. Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8:777861. doi:10.3389/fmed.2021.777861
8. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in non-diabetic patients with HFrEF (EMPA-TROPISM). J Am Coll Cardiol. 2021;9(8):578-589. doi:10.1016/j.jchf.2021.04.014
9. Murashima M, Tanaka T, Kasugai T, et al. SGLT2 inhibitors and anemia among diabetes patients in clinical practice. J Diabetes Investig. 2022; 13(4):638-646. doi:10.1111/jdi.13717
10. Kanbay M, Tapoi L, Ureche C, et al. Effect of SGLT2 inhibitors on hemoglobin and hematocrit in type 2 diabetes: meta-analysis. Int Urol Nephrol. 2022;54(4):827-841. doi:10.1007/s11255-021-02943-2
11. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
12. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
13. Zannad F, Ferreira JP, Pocock SJ, et al. Meta-analysis of EMPEROR-reduced and DAPA-HF. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9
14. Nassif ME, Windsor SL, Tang F, et al. DEFINE-HF trial. Circulation. 2019;140(18):1463-1476. doi:10.1161/CIRCULATIONAHA.119.042929
15. Anker SD, Butler J, Filippatos G, et al; EMPEROR-preserved trial investigators. Empagliflozin in HFpEF. N Engl J Med. 2021;385(16):1451-1461. doi:10.1161/CIRCULATIONAHA.121.056824
16. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER trial investigators. Dapagliflozin in HFpEF. N Engl J Med. 2022;387:1089-1098.
17. Nassif ME. Dapagliflozin in HFpEF: randomized trial (DEFINE-Preserved). JAMA. 2021;326:1959-1969.
18. Kosiborod MN. PRESERVED-HF trial. Circulation. 2021;144:1353-1365.
19. Borlaug BA. EMPERIAL-Preserved trial. Eur Heart J. 2020;41:2601-2612.
20. Jaiswal A, Jaiswal V, Ang SP, et al. SGLT2 inhibitors in HFpEF: meta-analysis. Medicine (Baltimore). 2023;102(39):e34693. doi:10.1097/MD. 0000000000034693
21. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC HF Guidelines. Eur Heart J. 2021;42(42):3599-3726. doi:10.1093/eurheartj/ehab670
22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA HF Guidelines. Circulation. 2022;145:e895-1032.
23. Maddox TM, Januzzi JL, Allen LA, et al. 2024 ACC consensus pathway for HFrEF. J Am Coll Cardiol. 2024;83(15):1444-1488. doi:10.1016/j.jacc. 2023.12.024
24. Mebazaa A. STRONG-HF trial. Lancet. 2022;400:1757-1769.
25. Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT2 inhibitors: safety review of real-world data and randomized clinical trials. Curr Probl Cardiol. 2024; 49(9):102664. doi:10.1016/j.cpcardiol.2024.102664
26. Buse JB, Wexler DJ, Tsapas A, et al. ADA-EASD consensus report. Diabetes Care. 2020;43(2):487-493. doi:10.2337/dci19-0066
27. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi:10.1016/j.ekir. 2022.04.094
28. von Lewinski D, Kolesnik E, Tripolt NJ, et al. EMMY trial. Eur Heart J. 2022;43(41):4421-4432. doi:10.1093/eurheartj/ehac494
29. Luo J, Feldman R, Callaway Kim K, et al. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw Open. 2023;6(6):e2317886. doi:10.1001/jamanetworkopen.2023. 17886
30. McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25(7):1830-1838. doi:10.1111/dom.15040
Article available in :
Volume 3, Issue 3, 2025
Page : 56-60
https://doi.org/10.51271/JCCVS-0059
Article Information
Received : 01 Eyl 2025
Accepted : 26 Eyl 2025
Published : 27 Eyl 2025
Corresponding Author :

Afnan Chaudhry: Department of Internal Medicine, Phoenexville Hospital Towerhealth, Phoenixville, PA, USA

[email protected]
Citation : Lawal OM, Ahmed HS, Alazzeh M, et al. Beyond glycemic control: SGLT2 inhibitors as foundational therapy in heart failure. J Cardiol Cardiovasc Surg. 2025;3(3):56-60.

Read: 160
Download : 63
Cited: 0
_Footer